← Back to Search

Vaccine

SHINGRIX (Zoster Vaccine REcombinant, Adjuvanted) for Shingles (NH-Shingrix Trial)

Phase < 1
Waitlist Available
Research Sponsored by Barbara Carlson
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up days 120 through 180
Awards & highlights

NH-Shingrix Trial Summary

This trial will test if the Shingrix vaccine can help protect people from getting sick from other diseases like COVID-19.

Eligible Conditions
  • Shingles
  • Allergy and Immunology
  • Coronavirus

NH-Shingrix Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~days 120 through 180
This trial's timeline: 3 weeks for screening, Varies for treatment, and days 120 through 180 for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Evidenced of active and trained innate immunity
Secondary outcome measures
Respiratory Disease Severity (6 month)

Side effects data

From 2012 Phase 3 trial • 6104 Patients • NCT01346592
27%
Injection site pain
25%
Pyrexia
14%
Decreased appetite
14%
Upper respiratory tract infection
14%
Diarrhea
10%
Injection site erythema
9%
Nasopharyngitis
9%
Irritability postvaccinal
9%
Headache
8%
Vomiting
8%
Injection site induration
7%
Myalgia
7%
Hypersomnia
7%
Injection site swelling
7%
Fatigue
6%
Crying
6%
Injection site hemorrhage
4%
Gastroenteritis
1%
Pneumonia
1%
Animal Bite
100%
80%
60%
40%
20%
0%
Study treatment Arm
ATIV (6 to <72 Months)
TIV (6 to <72 Months)
Comparator TIV (6 to <72 Months)

NH-Shingrix Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: ShingrixExperimental Treatment1 Intervention
Shingrix Dosage: two .5 ml injections into the deltoid muscle, administered 3 months apart (Day 0 and Day 90).
Group II: Normal SalinePlacebo Group1 Intervention
Sterile Normal Saline Solution, two .5 ml injections into the deltoid muscle, administered 3 months apart (Day 0 and Day 90)
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
SHINGRIX (Zoster Vaccine REcombinant, Adjuvanted)
2020
Completed Early Phase 1
~220

Find a Location

Who is running the clinical trial?

Barbara CarlsonLead Sponsor
Oklahoma Medical Research FoundationOTHER
21 Previous Clinical Trials
7,865 Total Patients Enrolled
University of OklahomaLead Sponsor
455 Previous Clinical Trials
97,393 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
Training the Innate Immune System Against SARS-CoV-2 (COVID-19) Using the Shingrix Vaccine in Nursing Home Residents
Barbara Carlson 2020. "Training the Innate Immune System Against SARS-CoV-2 (COVID-19) Using the Shingrix Vaccine in Nursing Home Residents". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04523246.
~47 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top